Consequently, these findings further emphasise the mitotic CIP2A-TOPBP1 axis as a promising therapeutic target in BRCA1/2-deficient cancers and those with elevated DNA replication stress, while highlighting actionable avenues for anti-cancer therapy development. Here, CIP2A is linked to cancer.